Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults

Netherlands Journal of Medicine

Volumn 66, Issue 9, 2008, Pages 378-383

  Hak, E ^a   Grobbee, D E ^a   Sanders, E A M ^a   Verheij, T J M ^a   Bolkenbaas, M ^a   Huijts, S M ^a   Gruber, W C ^b   Tansey, S ^b   McDonough, A ^b   Thoma, B ^b   Patterson, S ^b   van Alphen, A J ^c   Bonten, M J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b WYETH RESEARCH   (United States)

^c NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMMUNITY LIVING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH ECONOMICS; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

AGED; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 55049089930     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-55.
2. Jackson ML. Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results ofa population-based study. Clin Infect Dis. 2004;39:1642-50.
3. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomised, single-blind population-based trial. Am J Med. 1997;103:281-90.
4. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J. 2002;20(Suppl. 36):S20-7.
5. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003;3:71-8.
6. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 1984;101:325-30.
7. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988;108:653-57.
8. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325:1453-60.
9. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med. 1995;155:2336-40.
10. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med. 1986;104:1-6.
11. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993;270:1826-31.
12. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Eng J Med. 2003;348:1747-55.
13. Forrester HL, Jahnigen DW, Laforce MF. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med. 1987;83:425-30.
14. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999;17:2493-500.
15. Hak E, Bonten MJM, Hoes AW. Pneumococcal vaccination in older adults. N Engl J Med. 2003;349:712-4.
16. Health Council of the Netherlands. Pneumococcal vaccine in elderly adults and risk groups. The Hague: Health Council of the Netherlands, 2003.
17. De Roux A, Schmoele-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015-23.
18. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanents Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-95.
19. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-81.
20. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-8.
21. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139-46.
22. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-61.
23. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006;193:1487-94.
24. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043-51.
25. Bender JM, Ampofo K, Korgenski K, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis. 2008;46:1346-52.
26. Singleton RJ, Henessy TW, Bulkow LR, et al. invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-92.
27. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7:597-606.
28. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons with high-risk medical conditions under 65 years. The PRISMA study. Arch Intern Med. 2005;165:274-80.
29. Knottnerus JA, van Velden GH. Dutch doctors and their patients - effects of health care reform in the Netherlands. N Engl J Med. 200713;357(24):2424-6.
30. Renaud B, Coma E, Hayon J, et al. Investigation of the ability of the Pneumonia Severity Index to accurately predict clinically relevant outcomes: a European study. Clin Microbiol Infect. 2007;13:923-31.
31. Centers for Disease Control and Prevention. http://www.cdc.gov/ncidod/ dbmd/abcs/methodology.htm (last accessed 22 Jan 2008).